BETTA PHARMACEUTICALS
30055858.133.73% ( -2.25 )
BETTA PHARMACEUTICALS (300558)
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China and internationally. The compa...
- Open
- 59.61
- High
- 60.18
- Low
- 57.68
- Prev. Close
- 60.38
- Volume
- 108.01K
- Turnover
- 631.47M
- Avg Price
- 58.47
- Bid/Ask Ratio
- --
- Amplitude
- 4.14%
- 52wk High
- 79.65
- Volume Ratio
- 0.43
- Turnover Ratio
- 2.57%
BETTA PHARMACEUTICALS Analyst Rating
View MoreForecast & Rating
Jul 21, 2026Price forecast
¥43.06-25.92%
Forecast & Rating
1analysts
- Strong buy0.00%
- Buy0.00%
- Hold0.00%
- Sell100.00%
- Strong sell0.00%
News
- prnewswire · Jul 8 at 09:18 PM
22:16 ETGroundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of Medicine
- Zhitong · Oct 17, 2025 at 03:33 AM
BETTA PHARMACEUTICALS: The company currently does not have exclusive agency for foreign products
- Zhitong · Oct 14, 2025 at 01:11 AM
A-share innovative drug concept stocks fluctuated lower, with BETTA PHARMACEUTICALS falling over 10%, Jincheng Pharm, Konruns, Baillie Tianheng, Olymvax Biopharmaceuticals, and CCHT all dropping more than 5%
- Wallstreetcn · Sep 2, 2025 at 08:30 PM
BETTA PHARMACEUTICALS: Will strive for more new drug approvals in high-incidence tumor areas such as lung cancer and breast cancer
- Zhitong · Aug 27, 2025 at 05:40 AM
BETTA PHARMACEUTICALS: The first prescription for Enasidenib Hydrochloride Capsules has been issued in the United States
- Zhitong · Aug 24, 2025 at 07:04 PM
BETTA PHARMACEUTICALS: Clinical research on the postoperative adjuvant indication of ensartinib has made progress
